September 4-7 2018
Boston, MA

Twitter logo for website footers 2

Deep Dive Discussion Day

Pre-Conference Deep Dive Day Agenda

Tuesday, September 4th 2018

In order to drill down on the most crucial topics plaguing CAR-TCR development, we are offering a wide variety of deep dive sessions. These 2 hour sessions provide an enhanced learning experience and are a more intimate opportunity to not only learn from experts on key topic areas, but also to interact with them in a frank, open and peer level environment.

CAR-TCR Discovery Track

CAR-TCR Translation Track

CAR-TCR Manufacturing Track

CAR-TCR Transport,Logistics & Supply Chain Track

CAR-TCR Commercialization Track

9.00 – 11.00am 9.00 – 11.00am 9.00 – 11.00am 9.00 – 11.00am 9.00 – 11.00am
Optimizing Fuel
Selection for CAR-T Cell Metabolism

Roderick O’ Connor, Instructor,
Center for Cellular Immunotherapies,
University of Pennsylvania School of


How will gene editing take off-the-shelf allogeneic cell therapies to the next stage in the future?

David Sourdive, Executive Vice
President Technical Operations,
Vector Production
Challenges for Multi-Product Cell
Therapy Programs

Steven Feldman, Director, Surgery
Branch Vector Production Facility,
National Cancer Institute (NCI) in NIH
and Supply Chain Strategies for
Engineered T Cell Therapies

Bruce Levine, Founding Director
of the Clinical Cell and Vaccine
Production Facility (CVPF), University
of Pennsylvania
IP and Licensing:
Navigating the Landscape

Shawn Foley, Attorney, Intellectual
Property, Burns & Levinson
12.00 – 2.00pm 12.00 – 2.00pm 12.00 – 2.00pm 12.00 – 2.00pm 12.00 – 2.00pm
Bi-specific Adaptor
Controlled CAR-T Cell Therapy for Solid
and Liquid Tumors

Chris Leamon, Vice President of
Research, Endocyte
Optimizing the
Predictive Value of Preclinical
Models for Translation of Adoptive Immunotherapies into Human Trials

Avery Posey, Instructor-level Faculty,
University of Pennsylvania
Specifications for
Release Criteria

Therese Choquette, Analytical Project
Leader, Cell and Gene Therapy
Development and Manufacturing,
Manufacturing Of
Tcr Based T Cells For Solid Tumors:
Experience And Lessons Learned

Ali Mohamed, Vice President, CMC,
Immatics US Inc.
Innovation in
Reimbursement for Cellular
Therapies: a US Perspective

Edmund Pezalla, CEO & Founder of
Enlightenment Bioconsult, LLC


2.00 – 3.00pm Afternoon Refreshments & Debrief
3.00 – 5.00pm 3.00 – 5.00pm 3.00 – 5.00pm 3.00 – 5.00pm 3.00 – 5.00pm
Engineering T Cells for
Solid Tumor Applications, The End of
The Beginning

Rick Morgan, Vice President of
Immunotherapy, bluebird bio
The Challenges of
Correlative and Release Test Assays for
Evaluating Gene Edited Human Cell Products

Simon Lacey, Director Translational and
Correlative Studies Laboratory, Center
for Cellular Immunotherapies, UPenn
Confronting Analytical
Challenges of Chimeric Antigen
Receptor T Cell

Eileen Higham, Head of Analytical
and Process Development, Juno
Delivering Next
Generation CAR-T Therapies

Rodney Rietze, Enabling Technology and
Strategic Development, Novartis
Investigating the Regulatory Landscape of CAR-T Therapy

Gopalan Narayanan, Vice President,
Disruptive Biologics
 5.00pm Evening Refreshments & Debrief